ID   HRC45
AC   CVCL_IS24
SY   HRC-45
DR   Wikidata; Q54895228
RX   PubMed=21854714;
RX   PubMed=23657944;
RX   PubMed=27993170;
DI   NCIt; C4033; Clear cell renal cell carcinoma
DI   ORDO; Orphanet_319276; Clear cell renal carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   65Y
CA   Cancer cell line
DT   Created: 03-03-17; Last updated: 21-03-23; Version: 6
//
RX   PubMed=21854714; PMCID=PMC3182114;
RA   Canter, Daniel
RA   Kutikov, Alexander
RA   Golovine, Konstantin
RA   Makhov, Petr
RA   Simhan, Jay
RA   Uzzo, Robert G.
RA   Kolenko, Vladimir M.
RT   "Are all multi-targeted tyrosine kinase inhibitors created equal? An
RT   in vitro study of sunitinib and pazopanib in renal cell carcinoma cell
RT   lines.";
RL   Can. J. Urol. 18:5819-5825(2011).
//
RX   PubMed=23657944; DOI=10.1158/1535-7163.MCT-12-1010; PMCID=PMC3746800;
RA   Thapa, Roshan Jung
RA   Chen, Pei-Rong
RA   Cheung, Mitchell
RA   Nogusa, Shoko
RA   Pei, Jian-Ming
RA   Peri, Suraj
RA   Testa, Joseph R.
RA   Balachandran, Siddharth
RT   "NF-kappaB inhibition by bortezomib permits IFN-gamma-activated RIP1
RT   kinase-dependent necrosis in renal cell carcinoma.";
RL   Mol. Cancer Ther. 12:1568-1578(2013).
//
RX   PubMed=27993170; DOI=10.1186/s12943-016-0565-8; PMCID=PMC5168717;
RA   Brodaczewska, Klaudia Klarysa
RA   Szczylik, Cezary
RA   Fiedorowicz, Michal
RA   Porta, Camillo
RA   Czarnecka, Anna Malgorzata
RT   "Choosing the right cell line for renal cell cancer research.";
RL   Mol. Cancer 15:83.1-83.15(2016).
//